MAPT and Alzheimer disease: Our findings indicate increase in tau-positive cases in both methods along the AD spectrum, with SUVR progressively increased from A-CU to A + CI individuals, reflecting a well-established link between tau accumulation and clinical symptoms, regardless of the reference space selected in the processing pipeline, further supporting the value of tau-PET as staging marker in AD [25].